Страна: Канада
Язык: английский
Источник: Health Canada
ENALAPRIL MALEATE
PRO DOC LIMITEE
C09AA02
ENALAPRIL
2.5MG
TABLET
ENALAPRIL MALEATE 2.5MG
ORAL
100
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0117649004; AHFS:
APPROVED
2008-06-13
_PRO-ENALAPRIL (Enalapril Maleate Tablets_) _Page 1 of 49_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PRO-ENALAPRIL – 2.5, PR PRO-ENALAPRIL – 5, PR PRO-ENALAPRIL – 10, PR PRO-ENALAPRIL – 20 Enalapril Maleate Tablets Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg, oral USP Angiotensin Converting Enzyme Inhibitor PRO DOC LTÉE. 2925 Boulevard Industriel Laval, Quebec H7L 3W9 Submission Control Number: 277145 Date of Initial Authorization: JUN 13, 2008 Date of Revision: AUG 09, 2023 _PRO-ENALAPRIL (Enalapril Maleate Tablets_) _Page 2 of 49_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 08/2023 4 DOSAGE AND ADMINISTRATION 08/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS ............................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .......................................................... 5 4 DOSAGE AND ADMINISTRATION ............................................................................... 5 4.1 Dosing Considerations ............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ............................. Прочитать полный документ